Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, Debiopharm Ink Biomarker ID Deal

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix's expertise in combining high-throughput screening with high-content assays in cultured human cells will be applied to identify predictive biomarkers for Debiopharm's preclinical cancer candidates. Cenix has established multiparametric microscopy-based readouts using the Definiens XD image analysis platform, which will be used in human cancer cell models to identify genes and pathways that enhance or suppress a drug's therapeutic effects.

According to the partners, "the study represents another important illustration of Debiopharm's ongoing drive to integrate cutting edge technologies and powerful post-genomic strategies towards further refining its personalized medicine approach toward the development of new therapeutics."

Financial and other terms of the deal were not disclosed.

Cenix is a preclinical contract research organization with operations in Germany, Belgium, and the US and develops reagent technologies for cell-based and in vivo applications.